Beijing Beilu Pharmaceutical (SHE:300016) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Beilu Pharmaceutical (300016)
Beijing Beilu Pharmaceutical (SHE:300016) has a market capitalization of $630.92 Million (CN¥4.31 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11228 globally and #3186 in its home market, demonstrating a 1.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Beilu Pharmaceutical's stock price CN¥7.66 by its total outstanding shares 562873163 (562.87 Million). Review Beijing Beilu Pharmaceutical (300016) financial obligations to assess the company's total debt and financial obligations.
Beijing Beilu Pharmaceutical Market Cap History: 2015 to 2026
Beijing Beilu Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.86 Billion to $630.92 Million (-8.11% CAGR).
Beijing Beilu Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Beilu Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.52x
Beijing Beilu Pharmaceutical's market cap is 0.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
37.41x
Beijing Beilu Pharmaceutical's market cap is 37.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.86 Billion | $491.43 Million | $32.58 Million | 3.78x | 57.02x |
| 2016 | $967.05 Million | $498.86 Million | $16.38 Million | 1.94x | 59.04x |
| 2017 | $717.22 Million | $522.54 Million | $118.82 Million | 1.37x | 6.04x |
| 2018 | $551.66 Million | $608.05 Million | $147.76 Million | 0.91x | 3.73x |
| 2019 | $715.26 Million | $819.12 Million | $342.44 Million | 0.87x | 2.09x |
| 2020 | $765.66 Million | $827.34 Million | $174.70 Million | 0.93x | 4.38x |
| 2021 | $740.16 Million | $843.90 Million | $125.51 Million | 0.88x | 5.90x |
| 2022 | $531.44 Million | $765.88 Million | $11.28 Million | 0.69x | 47.10x |
| 2023 | $586.45 Million | $890.72 Million | -$71.76 Million | 0.66x | N/A |
| 2024 | $510.67 Million | $983.55 Million | $13.65 Million | 0.52x | 37.41x |
Competitor Companies of 300016 by Market Capitalization
Companies near Beijing Beilu Pharmaceutical in the global market cap rankings as of June 19, 2026.
Key companies related to Beijing Beilu Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Beijing Beilu Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Beilu Pharmaceutical's market cap moved from $1.86 Billion to $ 630.92 Million, with a yearly change of -8.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥630.92 Million | -3.53% |
| 2025 | CN¥653.99 Million | +28.06% |
| 2024 | CN¥510.67 Million | -12.92% |
| 2023 | CN¥586.45 Million | +10.35% |
| 2022 | CN¥531.44 Million | -28.20% |
| 2021 | CN¥740.16 Million | -3.33% |
| 2020 | CN¥765.66 Million | +7.05% |
| 2019 | CN¥715.26 Million | +29.65% |
| 2018 | CN¥551.66 Million | -23.08% |
| 2017 | CN¥717.22 Million | -25.83% |
| 2016 | CN¥967.05 Million | -47.94% |
| 2015 | CN¥1.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Beijing Beilu Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $630.92 Million USD |
| MoneyControl | $630.92 Million USD |
| MarketWatch | $630.92 Million USD |
| marketcap.company | $630.92 Million USD |
| Reuters | $630.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more